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Summary
Background Male circumcision is a primary HIV-1 prevention intervention for men, but whether the procedure 
reduces the risk of syphilis among men and their female partners is uncertain. We aimed to assess whether male 
circumcision was associated with incident syphilis in men and in their female partners.
Methods In this large prospective cohort study, participants were members of Kenyan and Ugandan HIV-1 
serodiscordant heterosexual couples enrolled in a randomised safety and eﬃ  cacy clinical trial of pre-exposure 
prophylaxis for HIV-1 prevention (the Partners PrEP Study). Participants attended monthly or quarterly follow-up 
visits for up to 36 months. Annually, syphilis serology testing was done and male circumcision status was assessed. 
We used multivariate Andersen-Gill survival methods, adjusted for age, sexual behaviour, and plasma HIV RNA 
levels of the HIV-infected partner.
Findings 4716 HIV-1 serodiscordant couples (38%) with a man with HIV were followed for a median of 2·75 years. At 
enrolment, 1575 (53%) men with HIV and 560 (32%) men without HIV were circumcised; an additional 69 (4%) men 
with HIV and 132 (5%) men without HIV were circumcised during study follow-up. 221 incident syphilis infections 
were reported: 46 (21%) in men with HIV (incidence 1·10 per 100 person-years), 76 (34%) in men without HIV (1·09), 
54 (24%) in women with HIV (0·77), and 45 (24%) in women without HIV (1·11). Male circumcision was associated 
with a 42% reduction in incident syphilis in men (adjusted hazard ratio [aHR] 0·58, 95% CI 0·37–0·91) including a 
62% reduction in men with HIV (0·38, 0·18–0·81), and a non-signiﬁ cant reduction in incident syphilis in men 
without HIV (0·64, 0·36–1·11). In women, circumcision of their male partners was associated with a 59% reduction 
in incident syphilis (aHR 0·41, 95% CI 0·25–0·69), including a 75% reduction in women without HIV (0·25, 
0·08–0·76) and a 48% reduction in women with HIV (0·52, 0·27–0·97).
Interpretation Male circumcision was associated with decreased risk of incident syphilis in men and women. If 
conﬁ rmed, these results suggest that medical male circumcision could substantially reduce incidence of syphilis and 
its sequelae.
Funding Bill & Melinda Gates Foundation and the Eunice Kennedy Shriver National Institute of Child Health and 
Human Development.
Copyright © Pintye et al. Open Access article distributed under the terms of CC BY-NC-ND.
Introduction
Data from more than 40 studies, including three 
randomised controlled trials, have shown that male 
circumcision provides at least 60% protection against 
acquisition of HIV-1 for heterosexual men.1–4 The 
consistently high eﬃ  cacy noted in the three randomised 
clinical trials was the impetus for WHO-UNAIDS 
recommendations in 2007 that medical male circumcision 
be a priority strategy for prevention of HIV and should be 
implemented in settings with low prevalence of male 
circumcision and high prevalence of HIV.5 Several 
observational studies also support a preventive role for 
male circumcision for other sexually transmitted 
infections (STIs), including human papillomavirus, 
herpes simplex virus type 2, Trichomonas vaginalis, 
chancroid, Mycoplasma genitalium, and genital ulcer 
disease in heterosexual men.6–13 Although a meta-analysis 
of randomised and observational studies concluded that 
there was no association between male circumcision and 
risk of HIV in women (summary relative risk 0·80, 
95% CI 0·53–1·36, heterogeneity p=0·05),14 a protective 
beneﬁ t of male circumcision on STI transmission to 
female partners has been reported. Data from randomised 
trials have shown reduced risk of human papillomavirus, 
genital ulcers, herpes simplex virus type 2, bacterial 
vaginosis, and T vaginalis in women whose partners are 
circumcised, whereas other observational studies did not 
show an association with bacterial vaginosis, T vaginalis, 
and Chlamydia trachomatis.15–21
The potential association between male circumcision 
and syphilis was ﬁ rst described in the mid-1850s in a 
medical report of patients with syphilis and Neisseria 
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gonorrhoeae in which a greater proportion of non-Jewish 
men had syphilis compared with Jewish men, who were 
presumed to be circumcised because of religious 
practices.22 Several recent studies, including one 
meta-analysis, have suggested that circumcised 
heterosexual men are at reduced risk of syphilis.9 
However, few studies have assessed the relation between 
male circumcision and incident syphilis status in men 
with HIV, and no studies to date have investigated the 
eﬀ ect of male circumcision in HIV-infected or HIV-
uninfected men on syphilis acquisition in women. A 
protective eﬀ ect of male circumcision on the risk of 
incident syphilis for HIV-infected and HIV-uninfected 
men and women could have important public health 
implications. Syphilis can lead to irreversible 
neurological and cardiovascular damage and syphilis 
during pregnancy can cause numerous adverse 
pregnancy and birth outcomes.23 Male circumcision is 
currently being implemented as a medical procedure in 
settings of sub-Saharan Africa with high HIV burden,24 
and in those settings syphilis prevalence is also often 
high. Evidence of additional beneﬁ ts against syphilis 
could enhance present medical male circumcision 
programmes. We aimed to investigate the association 
between male circumcision and incidence of syphilis in 
a HIV-infected and HIV-uninfected African men and 
their female partners.
Methods
Study design and participants
In this large prospective cohort study, participants were 
members of Kenyan and Ugandan HIV serodiscordant 
heterosexual couples enrolled in a randomised safety and 
eﬃ  cacy clinical trial of pre-exposure prophylaxis (PrEP) 
for HIV-1 prevention (the Partners PrEP Study).25,26 Trial 
recruitment, eligibility and exclusion criteria, and follow-
up procedures have been previously described.25 All 
couples received a comprehensive package of HIV 
prevention services, including individual and couples risk-
reduction counselling, screening and treatment for STIs, 
condoms, and referral for medical male circumcision and 
post-exposure prophylaxis according to national policies. 
At enrolment into the trial, HIV-infected partners were 
not eligible for antiretroviral therapy (ART) under the 
national ART guidelines during the study; they were 
referred for initiation of ART when they became eligible.
At an interim review, the trial’s independent data safety 
and monitoring board recommended that the placebo 
group be discontinued early because of clear dem-
onstration of PrEP eﬃ  cacy for HIV prevention.25 All 
participants were informed of the outcome and continued 
on active PrEP thereafter. Data through study completion 
(between 2008 and 2013) were included in this prospective 
analysis of male circumcision and incident syphilis.
The Partners PrEP Study protocol was approved by the 
University of Washington Human Subjects Review 
Committee and ethics review committees at all of the 
study sites.25 All participants provided written informed 
consent in English or their local language.
Procedures
HIV-uninfected participants attended monthly and HIV-
infected partners attended quarterly visits for up to 
36 months. Follow-up visits included standardised 
interviews about sexual behaviour in the past 30 days, 
medical history, and assessment of clinical and laboratory 
safety. Male circumcision status was determined by 
physical examination at the time of study enrolment and 
every annual follow-up visit and reported as fully 
circumcised, partially circumcised, or not circumcised. 
HIV-uninfected partners underwent HIV testing and 
were dispensed study medication. For HIV-infected 
partners, CD4 cell counts were quantiﬁ ed every 6 months 
with standard ﬂ ow cytometry and plasma HIV-1 RNA 
levels were quantiﬁ ed with the COBAS Ampliprep/
COBAS TaqMan real-time HIV-1 RNA assay (version 1.0; 
Roche Diagnostics, Indianapolis, IN, USA), with a lower 
limit of quantiﬁ cation of 240 copies per mL.
Detailed descriptions of the Partners PrEP Study STI 
diagnostic testing are provided elsewhere.26 Prevalent 
syphilis infection at enrolment was determined by a 
positive rapid plasma reagin (Immutrep RPR [Omega 
Diagnostics], BD Macro-Vue RPR [BD diagnostics], or 
Human RPR [Human Diagnostics]) titre and conﬁ rmed 
with a positive Treponema pallidum haemagglutination 
(Immutrep TPHA [Omega Diagnostics], Randox TPHA 
[Randox Laboratories], Human TPHA Liquid [Human 
Diagnostics], or Hexagon [Human Diagnostics]) assay 
result. Syphilis serology testing was done annually 
during follow-up visits and if clinically indicated during 
other study visits. Study participants with syphilis at 
enrolment were deemed to have a new incident infection 
during follow-up if the rapid plasma reagin titre increased 
by four-fold or more from the previous visit. For study 
participants with a negative rapid plasma reagin at 
enrolment, a positive rapid plasma reagin with a 
conﬁ rmatory positive T pallidum haemagglutination 
assay at a follow-up visit was deﬁ ned as an incident 
syphilis infection; and subsequent infections were 
deemed to be incident if a four-fold increase in rapid 
plasma reagin titre had occurred. Only incident non-
persistent syphilis infections detected through serological 
testing were included in the ﬁ nal analysis.
Statistical analysis
All couples in whom the circumcision status of the male 
partner was available were included in the statistical 
analysis for this study; a small number of couples with 
partially circumcised men were excluded. χ² tests for 
proportions and Kruskal-Wallis tests for continuous 
measures were used to detect diﬀ erences in 
demographic, behavioural, and medical characteristics 
between couples with circumcised versus un circumcised 
male partners at enrolment.
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Diﬀ erences in syphilis detected at enrolment in 
circumcised male partners versus uncircumcised male 
partners (or women with exposure to circumcised versus 
uncircumcised male partners) were assessed with 
multivariate logistic regression. To assess incident 
syphilis during follow-up, Andersen-Gill survival models 
were used to allow for multiple events per individual. 
Male circumcision status was analysed as a time-
dependent exposure variable, accounting for 
uncircumcised men who became circumcised during 
study follow-up. Separate analyses were done to compare 
syphilis incidence rates in HIV-infected and HIV-
uninfected men by their circumcision status and in HIV-
infected and HIV-uninfected women by whether their 
male partner was circumcised or uncircumcised. 
Diﬀ erences in the eﬀ ect of male circumcision on syphilis 
incidence between HIV-infected and HIV-uninfected 
study participants were assessed with a likelihood ratio 
test of interaction within our adjusted Andersen-Gill 
survival models. HIV-uninfected participants at 
enrolment who became HIV-infected during study 
follow up were censored at seroconversion. HIV-infected 
participants were observed throughout study follow-up 
regardless of partners’ seroconversion status.
We decided a priori to adjust our statistical models for 
age at enrolment, reported unprotected sex with the 
study partner in the past 30 days, and plasma HIV RNA 
concentration of the partner with HIV in the couple 
because of the known associations of these factors with 
male circumcision status or risk of STI or HIV 
transmission.27–30 Unprotected sex and HIV RNA 
concentration were analysed as time-dependent variables 













Age, male partner (years) 34 (29–40) 34 (28–41) 0·542 38 (33–44) 39 (34–45) 0·292
Age, female partner (years) 29 (24–34) 29 (24–35) 0·358 32 (27–37) 33 (28–39) 0·037
Years of school completed, male partner 8 (6–12) 7 (5–10) <0·0001 8 (6–11) 7 (4–9) <0·0001
Years of school completed, female partner 8 (5–10) 6 (3–6) <0·0001 7 (5–10) 5 (2–7) <0·0001
Enrolment site in Kenya (vs Uganda) 1082 (69%) 426 (31%) <0·0001 350 (61%) 228 (19%) <0·0001
Couple characteristics‡
Number of children together 1 (0–3) 2 (0–3) 0·001 3 (1–4) 3 (2–5) <0·0001
No children together 424 (23%) 364 (27%) 0·821 99 (17%) 162 (14%) 0·040
Married 1514 (96%) 1342 (98%) 0·006 564 (98%) 1182 (99%) 0·330
Cohabitating 1529 (97%) 1348 (98%) 0·026 566 (99%) 1176 (98%) 0·660
Sexual behaviour within partnership‡
Duration of sexual partnership (years) 6 (2–11) 6 (2–12) 0·442 11 (5–17) 12 (7–19) <0·0001
Coital frequency within couple, past month 4 (3–8) 4 (2–8) 0·068 4 (2–8) 2 (4–6) <0·0001
Reported unprotected sex with study partner, past 
month
383 (24%) 461 (34%) <0·0001 111 (19%) 290 (24%) 0·021
Reported sex with an additional partner, past 
month, male partner
181 (11%) 212 (15%) 0·002 62 (11%) 200 (17%) 0·001
Reported sex with an additional partner, past 
month, female partner
13 (1%) 16 (1%) 0·349 4 (1%) 4 (1%) 0·287
HIV characteristics
CD4 cell count (cells per μL)§ 454 (358–588) 458 (351–598) 0·783 523 (392–693) 533 (399–716) 0·167
Plasma HIV-1 RNA (log10 copies per mL)§ 4·0 (3·2–4·6) 4·2 (3·5–4·8) <0·0001 3·7 (2·9–4·3) 3·8 (3·2–4·4) <0·0001
ART use during study§ 569 (36%) 491 (36%) 0·831 209 (36%) 492 (41%) 0·055
Randomised to active PrEP group¶ 1069 (68%) 918 (67%) 0·597 373 (65%) 781 (65%) 0·895
Medical characteristics
Ever pregnant during study period 578 (37%) 529 (39%) 0·292 134 (23%) 261 (23%) 0·472
Curable STI at enrolment
Male partner|| 97 (6%) 67 (5%) 0·149 19 (3%) 29 (2%) 0·300
Female partner|| 149 (10%) 178 (14%) <0·0001 35 (6%) 109 (10%) 0·015
Data are median (IQR) or N (%). *Missing data not shown. †25 couples were excluded because the male partner was “partially” circumcised (11 couples with HIV-infected 
male partner and 14 couples with HIV uninfected male partner). ‡Couple sexual behaviour and demographic characteristics as reported by female partner. §Among 
HIV-infected male or female partners only. ¶Among HIV-uninfected male or female partners only. ||Includes Neisseria gonorrhoeae, Chlamydia trachomatis, and 
Trichomonas vaginalis.
Table 1: Enrolment characteristics of serodiscordant couples with documented male circumcision status*†
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as reported at the follow-up visit when syphilis testing 
was done. For participants who did not have HIV, we 
included the HIV RNA concentration of the partner with 
HIV. Additionally, we identiﬁ ed several demographic, 
behavioural, and medical characteristics to assess as 
potential confounders: pregnancy during follow-up in 
female partners, marital status, cohabitation with study 
partner, number of children with study partner, reported 
sex with an outside partner, CD4 cell count of the partner 
with HIV, PrEP study group assignment, herpes simplex 
virus-2 status at enrolment, infection with a curable STI 
(N gonorrhoeae, C trachomatis, or T vaginalis) at 
enrolment, and HIV-1 seroconversion of the partner 
without HIV during follow-up. None of these additional 
potential confounders were included in the ﬁ nal models 
because they did not substantially change the logistic 
regression model odds ratio or survival model hazard 
ratios (<10% change).
To examine the robustness of our Andersen-Gill models, 
we repeated the primary analysis with Poisson generalised 
estimating equation regression models for interval-
censored failure time data.31 We also did sensitivity analyses 
by excluding cases with a subsequent four-fold titre 
increase in rapid plasma reagin after previously detected 
incident syphilis to reduce potential misclassiﬁ cation due 
to treatment failure; by restricting the analysis to study 
participants whose partners had serological evidence of 
syphilis infection to examine the eﬀ ect of male 
circumcision on syphilis infections with the clearest 
evidence of linkage within the study partnerships; and by 
restricting the analysis to men who became circumcised 
during follow-up to examine the eﬀ ect of the period 
immediately following the medical male circumcision 
procedure on syphilis acquisition and transmission. Data 
were analysed with STATA 13.1/MP for Windows (Stata 
Corporation, College Station, TX, USA).
Role of the funding source
The funder had no involvement in the study design, data 
collection or analysis, interpretation of results, and 
writing of this report. The corresponding author had full 
access to all data in the study and had ﬁ nal responsibility 
for the decision to submit for publication without 
involvement of the funding source.
Results
4716 couples (99% of couples in the clinical trial) met 
criteria for inclusion in this analysis, of whom the HIV-
infected partner was female in 2946 couples and male in 
1770 couples (table 1); 31 were excluded because of 
missing data or for having a “partial” male circumcision 
status. The median age at enrolment was 30 years 
(IQR 25–36) for women and 36 years (30–42) for men; 
most (98%) couples were married and had a median of 
two children (IQR 1–4) together. The median number of 
sex acts in the previous month was four (IQR 2–8) and 
1245 (26%) of couples reported unprotected sex. 655 (14%) 
of men and 37 (<1%) of women reported having sex with 
an outside partner in the month before enrolment. 212 
(5%) men had other curable STIs and 471 (10%) of women 
(52 [1%] men and 37 [<1%] women had C trachomatis, 
39 (<1%) men and 75 (2%) women had N gonorrhoeae, and 
214 (5%) men and 381 (8%) women had T vaginalis).
At enrolment, 2149 (46%) men were circumcised 
(574 [32%] had HIV and 1575 [54%] did not have HIV; 
table 1). Couples with circumcised men were more 
educated, more often from Kenya, had more children, 
reported unprotected sex with the study partner less 
frequently in the past month, had male partners that 
reported sex with an additional partner less frequently, 
had lower plasma HIV-1 RNA concentration of HIV-
infected partners, and had a lower prevalence of curable 
STIs among female partners (table 1).
Circumcised men with and without HIV had a lower 
prevalence of syphilis at enrolment than those who were 
uncircumcised (table 2). This same pattern was noted 
in women.
1645 men with HIV, 2744 men without HIV, 
1643 women without HIV, and 2773 women with HIV 
had complete information about male partner 
circumcision status, at least one syphilis serology result, 
and sexual behaviour data during study follow-up and 
were included in the ﬁ nal analysis of incident syphilis 
risk (table 3). The median time that participants were in 
Total Uncircumcised Circumcised Crude Adjusted*
OR (95% CI) p value OR (95% CI) p value
All men (n=4682) 196 (4%) 152 (6%) 44 (2%) 0·33 (0·24–0·47) <0·0001 0·37 (0·26–0·52) <0·0001
HIV-infected men (n=1759) 98 (6%) 87 (7%) 11 (2%) 0·25 (0·13–0·47) <0·0001 0·25 (0·17–0·36) <0·0001
HIV-uninfected men (n=2923) 98 (3%) 65 (5%) 33 (2%) 0·42 (0·27–0·63) <0·0001 0·51 (0·40–0·66) <0·0001
All women (n=4696) 181 (4%) 141 (5%) 40 (2%) 0·33 (0·23–0·47) <0·0001 0·37 (0·26–0·53) <0·0001
HIV-infected women (n=2935) 100 (3%) 74 (5%) 26 (2%) 0·30 (0·19–0·47) <0·0001 0·35 (0·27–0·46) <0·0001
HIV-uninfected women (n=1761) 81 (5%) 67 (6%) 14 (3%) 0·41 (0·23–0·74) 0·003 0·45 (0·37–0·64) <0·0001
Data are N (%), unless otherwise stated. OR=odds ratio. *Adjusted model includes: age, plasma HIV-1 RNA (log10 copies/mL) of HIV-infected partner, and reported 
recent unprotected sex with study partner. 
Table 2: Prevalent syphilis—proportion of men and women with serological evidence of syphilis at enrolment and association with male partner 
circumcision status, by enrolment HIV serostatus
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the study was 2·75 years (IQR 2·30–2·79). 221 incident 
syphilis infections were reported: 46 (21%) in men with 
HIV (incidence 1·10 per 100 person-years), 76 (34%) in 
men without HIV (1·09), 54 (24%) in women with HIV 
(0·77), and 45 (24%) in women without HIV (1·11). 
21 individuals had more than one incident syphilis 
infection during follow-up (nine women and 12 men).
Overall, male circumcision was associated with a 42% 
reduction in incident syphilis in men (table 3), 
including a 62% reduction in men with HIV (aHR 0·38, 
95% CI 0·18–0·81) and a non-signiﬁ cant reduction in 
incident syphilis in men without HIV (0·64, 0·36–1·11). 
No signiﬁ cant diﬀ erence was noted between the eﬀ ect 
of male circumcision on syphilis incidence between 
HIV-infected and HIV-uninfected men (likelihood ratio 
pinteraction=0·26). Among women, circumcision of their 
male partners was associated with a 59% reduction in 
incident syphilis, including a 75% reduction among 
HIV-uninfected women (aHR 0·25, 95% CI 0·08–0·76) 
and a 48% reduction among HIV-infected women 
(0·52, 0·27–0·97). The eﬀ ect of male circumcision on 
syphilis incidence between HIV-infected and HIV-
uninfected women was not signiﬁ cantly diﬀ erent 
(likelihood ratio pinteraction=0·17). Analysis with Poisson 
generalised estimating equations regression models for 
interval-censored failure time data produced results 
that were very similar to all Andersen-Gill models (data 
not shown).
To reduce potential misclassiﬁ cation of rapid plasma 
reagin titre increases representing syphilis treatment 
failure rather than new infections, we excluded cases 
with a subsequent four-fold titre increase in rapid 
plasma reagin after previously detected incident syphilis. 
Results were similar to those from the full cohort: for 
HIV-infected men, the adjusted HR was 0·43, 95% CI 
0·19–0·99 (36 events) for HIV-uninfected men, the 
adjusted HR was 0·58, 95% CI 0·33–1·04 (47 events), for 
HIV-infected women, the adjusted HR was 0·56, 95% CI 
0·29–1·06 (38 events) and for HIV-uninfected women, 
the adjusted HR was 0·28, 95% CI 0·10–0·84 (32 events). 
To reduce potential misclassiﬁ cation of syphilis 
acquisition from outside partners, we restricted the 
cohort to study participants whose partners had 
serological evidence of syphilis infection. Results were 
of similar magnitude to those from the full cohort, 
although power was restricted: for HIV-infected men, 
the adjusted HR was 0·39, 95% CI 0·06–2·47 (nine 
events in 84 men), for HIV-uninfected men, the adjusted 
HR was 1·18, 95% CI 0·34–4·14 (19 events in 111 men), 
for HIV-infected women, the adjusted HR was 0·73, 
95% CI 0·24–2·23 (15 events in 115 women), and for 
HIV-uninfected women, the adjusted HR was 0·85, 
95% CI 0·09–8·32 (ten events in 103 women).
69 (4%) men with HIV and 132 (5%) men without HIV 
were circumcised during study follow-up and no incident 
syphilis infections were reported in their female partners. 
Two of 76 incident syphilis infections among HIV-
uninfected men and two of 46 incident syphilis infections 
among HIV-1 infected men were among men who 






100 person-years (95% CI)
Unadjusted Adjusted* pinteraction†
HR (95% CI) p value HR (95% CI) p value
All men (n=4389) 122 11 153·8 1·09 (0·92–1·31) ·· ·· ·· ·· ··
Circumcised 44 5514·6 0·80 (0·59–1·07) 0·57 (0·36–0·89) 0·012 0·58 (0·37–0·91) 0·017 0·26
Uncircumcised 78 5586·6 1·40 (1·12–1·74) 1·00 ·· ·· ·· ··
Men with HIV (n=1645) 46 4199·8 1·10 (0·82–1·46) ·· ·· ·· ·· ··
Circumcised 8 1489·7 0·54 (0·27–1·07) 0·38 (0·18–0·81) 0·012 0·38 (0·18–0·81) 0·013 ··
Uncircumcised 38 2680·1 1·42 (1·03–1·95) 1·00 ·· ·· ·· ··
Men without HIV (n=2744) 76 6953·9 1·09 (0·87–1·37) ·· ·· ·· ·· ··
Circumcised 36 4024·9 0·89 (0·65–1·24) 0·64 (0·37–1·12) 0·118 0·64 (0·36–1·11) 0·115 ··
Uncircumcised 40 2906·5 1·38 (1·01–1·88) 1·00 ·· ·· ·· ··
All women (n=4416) 99 11132·0 0·89 (0·73–1·08) ·· ·· ·· ·· ··
Circumcised male partners 28 5484·8 0·51 (0·35–0·74) 0·40 (0·24–0·68) 0·012 0·41 (0·25–0·69) 0·001 0·17
Uncircumcised male partners 71 5598·9 1·27 (1·00–1·60) ·· ·· ·· ·· ··
Women with HIV (n=2773) 54 7062·8 0·77 (0·59–1·00) ·· ·· ·· ·· ··
Circumcised male partners 22 4075·1 0·54 (0·36–0·82) 0·50 (0·27–0·94) 0·033 0·52 (0·27–0·97) 0·040 ··
Uncircumcised male partners 32 2964·5 1·08 (0·76–1·53) 1·00 ·· ·· ·· ··
Women without HIV (n=1643) 45 4069·3 1·11 (0·82–1·48) ·· ·· ·· ·· ··
Circumcised male partners 6 1409·7 0·43 (0·19–0·95) 0·29 (0·10–0·85) 0·024 0·25 (0·08–0·76) 0·014 ··
Uncircumcised male partners 39 2634·5 1·48 (1·08–2·03) 1·00 ·· ·· ·· ··
HR=hazard ratio. *Adjusted model includes age, plasma HIV-1 RNA (log10 copies per mL) of HIV-infected partner, and reported recent unprotected sex with study partner. 
†Likelihood ratio test assessed diﬀ erence in the eﬀ ect of male circumcision on syphilis incidence between HIV infected and uninfected study participants.
Table 3: Incident syphilis—rate of syphilis during follow-up and risk estimates of male partner circumcision status, by enrolment HIV serostatus
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infections were detected at the same annual visit when 
men were ﬁ rst documented to be circumcised. When we 
restricted our analysis to men who became circumcised 
during study follow-up, the results were qualitatively 
similar to those of the primary analysis.
Discussion
In this large prospective study from east Africa, male 
circumcision was associated with reduced prevalence 
and incidence of syphilis for men and women (panel). 
The magnitude of risk reduction associated with male 
circumcision ranged from 40% to 75% and was 
statistically signiﬁ cant in all groups except for HIV-
uninfected men for whom a trend towards a protective 
beneﬁ t was noted. Data assessing the relation between 
male circumcision and incident syphilis risk for HIV-
infected men and female partners of men with and 
without HIV infection are few, and thus our ﬁ ndings 
provide important new information about the medical 
beneﬁ ts of male circumcision.
There is a clear biological rationale for why male 
circumcision could protect against ulcerative STIs, such as 
syphilis. Uncircumcised men could be at increased risk 
because of penetration of pathogens through the inner 
surface of the foreskin and frenulum, or through 
microabrasions to the thinner epithelium lining the 
foreskin occurring during intercourse.9 The warm, moist 
area under the foreskin could provide an environment that 
encourages replication of T pallidum and other pathogens. 
Male circumcision might reduce transmissibility to female 
partners by reducing the surface area of the glans where 
spirochete-containing ulcers can form. At the population 
level, male circumcision could beneﬁ t women by reducing 
their risk of exposure to syphilis through reducing the risk 
of syphilis in their male partners. Present WHO guidelines 
recommend male circumcision programmes for HIV 
prevention among heterosexual men in settings with a 
high HIV/AIDS burden.5,14 The eﬀ ect of male circumcision 
programmes in reducing syphilis incidence and secondary 
transmission, in addition to HIV incidence among 
heterosexual men, could potentially have important public 
health implications and warrants future investigation.
Several studies have examined associations between 
male circumcision and incidence of non-HIV STIs.32 A 
meta-analysis of studies reporting on the association of 
male circumcision and syphilis, essentially among HIV-
uninfected men, reported a summary relative risk of 0·69 
(95% CI 0·50–0·94) similar to our ﬁ ndings.9 Two previous 
randomised trials have assessed the eﬀ ect of male 
circumcision (versus delayed male circumcision) on 
syphilis acquisition among HIV-uninfected men; neither 
found a protective eﬀ ect: adjusted HR 1·10, 95% CI 
0·75–1·65 and risk ratio 1·23, 95% CI 0·41–3·65.8,10 Both 
randomised trials excluded men who were HIV-infected 
or T pallidum-infected at baseline and reported low 
detection of syphilis at follow up. Our study did not have 
these exclusion requirements, and thus our participants 
could have had greater syphilis exposure, allowing 
observation of the eﬀ ect of male circumcision on syphilis 
risk that was not possible in the recent clinical trials.
This is the ﬁ rst study to our knowledge that has 
reported a statistically signiﬁ cant reduced risk of 
incident syphilis among female partners with 
circumcised male partners. Syphilis prevention in 
women continues to be an important goal. Several 
longitudinal studies and ongoing national-level surveys 
have established syphilis and HIV comorbidity among 
women in sub-Saharan Africa.33,34 Additionally, there are 
approximately 1 million new cases of congenital syphilis 
annually warranting further research on risk factors for 
syphilis among women and identiﬁ cation and 
implementation of eﬀ ective interventions.35 Eﬀ orts to 
promote medical male circumcision should emphasise 
the other reproductive health beneﬁ ts to men and their 
female partners, including syphilis prevention, in 
addition to HIV prevention.
Limitations of our study included the annual 
assessment of male circumcision status, which reduced 
our ability to precisely determine when initially 
uncircumcised men became circumcised. We tested for 
syphilis annually and when clinically indicated but 
generally had restricted ability to detect all incident 
syphilis infections, especially infections that could have 
occurred between testing intervals, some of which were 
potentially treated by outside providers or indirectly 
treated with antibiotics prescribed for other medical 
conditions. Although our data are from couples, the 
1-year interval between syphilis testing and absence of 
laboratory testing to link syphilis infections complicates 
Panel: Research in context
Systematic review
We searched PubMed with the terms “male circumcision”, “syphilis”, “acquisition”, “risk”, 
and “female partners”, for articles published between Jan 1, 1950, and June 30, 2014. Only 
articles available in English through original publication or translation were included. We 
identiﬁ ed one meta-analysis synthesising studies between January, 1950, and  April, 
2004, that reported a signiﬁ cant summary measure showing a protective eﬀ ect of male 
circumcision on syphilis infection in men.9 Two additional prospective studies published 
since this meta-analysis used randomised study designs to assess the relation between 
male circumcision and syphilis acquisition in HIV-1 uninfected men.8,10 These studies 
showed no diﬀ erence in the rate of syphilis incidence in men without HIV who were 
randomised to immediate versus delayed medical male circumcision. We did not identify 
any studies that investigated the relation between male circumcision status and risk of 
syphilis in men with HIV or the relation between male circumcision status and risk of 
syphilis in female partners.
Interpretation
In this large prospective study, male circumcision protected against syphilis acquisition 
in HIV infected and uninfected men and women. If conﬁ rmed by other studies, our 
results suggest that male circumcision could play an important part in syphilis control 
and could enhance the public health beneﬁ ts of this eﬀ ective intervention, particularly in 
settings with high HIV/AIDS comorbidity and where congenital syphilis persists as a 
public health problem.
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our ability to link syphilis infections within couples. 
Thus, some misclassiﬁ cation could have occurred in 
assessment of male circumcision and incident syphilis if 
partners acquired syphilis from an outside partner whose 
male circumcision status was unknown. Results from 
our subanalyses restricted to study participants whose 
partners had previous evidence of syphilis infection were 
similar to those from our primary models although with 
limited power. Additionally, our study participants were 
mutually disclosed HIV-serodiscordant heterosexual 
African couples and therefore further data are needed to 
conﬁ rm our results in other populations.
In conclusion, we identiﬁ ed a consistent protective 
eﬀ ect of male circumcision on syphilis incidence among 
HIV-infected and HIV-uninfected men and women. Our 
results add to the body of evidence that male circumcision 
prevents STIs in populations beyond HIV-uninfected 
men. If conﬁ rmed, our results suggest that male 
circumcision could signiﬁ cantly reduce syphilis 
incidence and related sequelae in both men and their 
female partners. A reduction in syphilis infection for 
men and women via male circumcision could have 
important implications for syphilis control and 
enhancing the public health beneﬁ ts of this eﬀ ective 
intervention, particularly in settings with high HIV/
AIDS comorbidity and where congenital syphilis persists 
as a public health problem.
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